Do analysts rate ABEO or BNR?

Abeona Therapeutics presently has a consensus target price of $19.00, suggesting a potential upside of 194.80%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Abeona Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abeona Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate BNR or IPSC?

Century Therapeutics has a consensus target price of $4.75, suggesting a potential upside of 138.10%. Given Century Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Century Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Century Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Do analysts rate BNR or AKBA?

Akebia Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 319.93%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Akebia Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts rate ELYM or BNR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend DMAC or BNR?

DiaMedica Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 76.06%. Given DiaMedica Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe DiaMedica Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DiaMedica Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Burning Rock Biotech (BNR) Competitors

$9.72 -0.21 (-2.06%)

As of 12:29 PM Eastern

Compare

BNR vs. ABEO, IPSC, AKBA, ELYM, and DMAC

Should you buy Burning Rock Biotech stock or one of its competitors? Burning Rock Biotech's main competitors and comparable companies include Abeona Therapeutics (ABEO), Century Therapeutics (IPSC), Akebia Therapeutics (AKBA), Eliem Therapeutics (ELYM), and DiaMedica Therapeutics (DMAC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Burning Rock Biotech compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Abeona Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market.

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Abeona Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. Burning Rock Biotech's return on equity of -10.98% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Burning Rock Biotech	-11.57%	-10.98%	-7.33%

Abeona Therapeutics has higher earnings, but lower revenue than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	63.11	$71.18M	$0.97	6.64
Burning Rock Biotech	$77.16M	1.33	-$7.92M	-$0.82	N/A

Abeona Therapeutics presently has a consensus target price of $19.00, suggesting a potential upside of 194.80%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Abeona Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Abeona Therapeutics had 4 more articles in the media than Burning Rock Biotech. MarketBeat recorded 5 mentions for Abeona Therapeutics and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.89 beat Abeona Therapeutics' score of 0.47 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Abeona Therapeutics	Neutral
Burning Rock Biotech	Very Positive

Summary

Abeona Therapeutics beats Burning Rock Biotech on 11 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to Century Therapeutics?

Burning Rock Biotech (NASDAQ:BNR) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Century Therapeutics has a consensus target price of $4.75, suggesting a potential upside of 138.10%. Given Century Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Century Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Century Therapeutics had 4 more articles in the media than Burning Rock Biotech. MarketBeat recorded 5 mentions for Century Therapeutics and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.89 beat Century Therapeutics' score of -0.01 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Burning Rock Biotech	Very Positive
Century Therapeutics	Neutral

30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by company insiders. Comparatively, 2.4% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Burning Rock Biotech has higher earnings, but lower revenue than Century Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.33	-$7.92M	-$0.82	N/A
Century Therapeutics	$109.16M	3.30	-$9.58M	-$1.14	N/A

Burning Rock Biotech has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

Century Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. Burning Rock Biotech's return on equity of -10.98% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
Century Therapeutics	N/A	-49.89%	-37.42%

Summary

Century Therapeutics beats Burning Rock Biotech on 10 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to Akebia Therapeutics?

Burning Rock Biotech (NASDAQ:BNR) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Burning Rock Biotech has a net margin of -11.57% compared to Akebia Therapeutics' net margin of -13.54%. Burning Rock Biotech's return on equity of -10.98% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

In the previous week, Akebia Therapeutics had 12 more articles in the media than Burning Rock Biotech. MarketBeat recorded 13 mentions for Akebia Therapeutics and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.89 beat Akebia Therapeutics' score of 0.06 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Burning Rock Biotech	Very Positive
Akebia Therapeutics	Neutral

Akebia Therapeutics has higher revenue and earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.33	-$7.92M	-$0.82	N/A
Akebia Therapeutics	$236.20M	1.05	-$5.34M	-$0.11	N/A

Akebia Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 319.93%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Burning Rock Biotech has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market.

Summary

Akebia Therapeutics beats Burning Rock Biotech on 9 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to Eliem Therapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Burning Rock Biotech has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Burning Rock Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Burning Rock Biotech	$77.16M	1.33	-$7.92M	-$0.82	N/A

Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Eliem Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. Burning Rock Biotech's return on equity of -10.98% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Burning Rock Biotech	-11.57%	-10.98%	-7.33%

In the previous week, Burning Rock Biotech had 1 more articles in the media than Eliem Therapeutics. MarketBeat recorded 1 mentions for Burning Rock Biotech and 0 mentions for Eliem Therapeutics. Burning Rock Biotech's average media sentiment score of 1.89 beat Eliem Therapeutics' score of 0.00 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Burning Rock Biotech	Very Positive

Summary

Burning Rock Biotech beats Eliem Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Burning Rock Biotech compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Burning Rock Biotech has higher revenue and earnings than DiaMedica Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Burning Rock Biotech	$77.16M	1.33	-$7.92M	-$0.82	N/A

DiaMedica Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market.

DiaMedica Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 76.06%. Given DiaMedica Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe DiaMedica Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

DiaMedica Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. Burning Rock Biotech's return on equity of -10.98% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-72.75%	-65.74%
Burning Rock Biotech	-11.57%	-10.98%	-7.33%

In the previous week, DiaMedica Therapeutics had 19 more articles in the media than Burning Rock Biotech. MarketBeat recorded 20 mentions for DiaMedica Therapeutics and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.89 beat DiaMedica Therapeutics' score of 0.85 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
DiaMedica Therapeutics	Positive
Burning Rock Biotech	Very Positive

Summary

Burning Rock Biotech beats DiaMedica Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Burning Rock Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNR vs. The Competition

Export

Metric	Burning Rock Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$102.31M	$3.74B	$7.05B	$13.04B
Dividend Yield	N/A	3.76%	2.58%	10.74%
P/E Ratio	-11.86	10.37	269.12	25.13
Price / Sales	1.33	1,269.90	643.33	105.53
Price / Cash	N/A	102.94	70.59	50.58
Price / Book	1.34	18.08	13.25	6.24
Net Income	-$7.92M	-$13.23M	$3.45B	$347.60M
7 Day Performance	9.52%	2.71%	2.10%	1.71%
1 Month Performance	-8.77%	1.23%	1.21%	0.87%
1 Year Performance	40.74%	54.90%	67.97%	19.68%

Burning Rock Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNR Burning Rock Biotech	1.3666 of 5 stars	$9.73 -2.1%	N/A	+41.8%	$102.31M	$77.16M	N/A	1,390	Positive News Gap Down
ABEO Abeona Therapeutics	2.8642 of 5 stars	$6.82 +6.7%	$19.00 +178.6%	+16.9%	$364.20M	$5.82M	7.03	90	News Coverage Earnings Report Gap Down
IPSC Century Therapeutics	1.4602 of 5 stars	$2.01 +1.5%	$4.75 +136.3%	+278.4%	$357.10M	$109.16M	N/A	170	News Coverage Earnings Report
AKBA Akebia Therapeutics	2.1745 of 5 stars	$1.33 +1.1%	$4.67 +252.2%	-73.1%	$351.42M	$236.20M	N/A	430	Analyst Revision
ELYM Eliem Therapeutics	N/A	$11.81 -0.8%	N/A	+739.4%	$351.37M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNR) was last updated on 8/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Burning Rock Biotech (BNR) Competitors

BNR vs. ABEO, IPSC, AKBA, ELYM, and DMAC

How does Burning Rock Biotech compare to Abeona Therapeutics?

Summary

How does Burning Rock Biotech compare to Century Therapeutics?

Summary

How does Burning Rock Biotech compare to Akebia Therapeutics?

Summary

How does Burning Rock Biotech compare to Eliem Therapeutics?

Summary

How does Burning Rock Biotech compare to DiaMedica Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Burning Rock Biotech (BNR) Competitors

BNR vs. ABEO, IPSC, AKBA, ELYM, and DMAC

How does Burning Rock Biotech compare to Abeona Therapeutics?

Which has more risk and volatility, ABEO or BNR?

Do insiders & institutionals hold more shares of ABEO or BNR?

Is ABEO or BNR more profitable?

Which has stronger earnings & valuation, ABEO or BNR?

Do analysts rate ABEO or BNR?

Does the media favor ABEO or BNR?

Summary

How does Burning Rock Biotech compare to Century Therapeutics?

Do analysts rate BNR or IPSC?

Does the media prefer BNR or IPSC?

Do institutionals and insiders believe in BNR or IPSC?

Which has stronger valuation & earnings, BNR or IPSC?

Which has more risk & volatility, BNR or IPSC?

Is BNR or IPSC more profitable?

Summary

How does Burning Rock Biotech compare to Akebia Therapeutics?

Is BNR or AKBA more profitable?

Does the media refer more to BNR or AKBA?

Which has higher earnings & valuation, BNR or AKBA?

Do analysts rate BNR or AKBA?

Do insiders and institutionals hold more shares of BNR or AKBA?

Which has more volatility & risk, BNR or AKBA?

Summary

How does Burning Rock Biotech compare to Eliem Therapeutics?

Which has better earnings & valuation, ELYM or BNR?

Which has more volatility and risk, ELYM or BNR?

Do analysts rate ELYM or BNR?

Do insiders & institutionals have more ownership in ELYM or BNR?

Is ELYM or BNR more profitable?

Does the media favor ELYM or BNR?

Summary

How does Burning Rock Biotech compare to DiaMedica Therapeutics?

Do insiders and institutionals believe in DMAC or BNR?

Which has preferable earnings & valuation, DMAC or BNR?

Which has more volatility & risk, DMAC or BNR?

Do analysts recommend DMAC or BNR?

Is DMAC or BNR more profitable?

Does the media favor DMAC or BNR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools